Sanofi Cash Flow from Operating Activities 2010-2025 | SNY
Sanofi annual/quarterly cash flow from operating activities history and growth rate from 2010 to 2025. Cash flow from operating activities can be defined as a company's cash flows from operations.
- Sanofi cash flow from operating activities for the quarter ending March 31, 2025 was $2.205B, a 0% increase year-over-year.
- Sanofi cash flow from operating activities for the twelve months ending March 31, 2025 was $13.564B, a 9.5% decline year-over-year.
- Sanofi annual cash flow from operating activities for 2024 was $9.827B, a 11.49% decline from 2023.
- Sanofi annual cash flow from operating activities for 2023 was $11.102B, a 0.11% increase from 2022.
- Sanofi annual cash flow from operating activities for 2022 was $11.09B, a 10.91% decline from 2021.
Sanofi Annual Cash Flow Ops
(Millions of US $) |
| 2024 |
$9,827 |
| 2023 |
$11,102 |
| 2022 |
$11,090 |
| 2021 |
$12,449 |
| 2020 |
$8,509 |
| 2019 |
$8,673 |
| 2018 |
$6,551 |
| 2017 |
$8,340 |
| 2016 |
$8,674 |
| 2015 |
$9,205 |
| 2014 |
$10,222 |
| 2013 |
$9,237 |
| 2012 |
$10,509 |
| 2011 |
$12,980 |
| 2010 |
$12,959 |
| 2009 |
$11,875 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharma |
$140.056B |
$44.458B |
|
Sanofi-Aventis manufactures & markets prescription drugs across countries. It focuses on major therapeutic areas such as multiple sclerosis, cardiovascular, immunology, neurology, oncology, rare blood disorders & diabetes, etc. By taking Genzyme Corporation as a subsidiary, it added products like Cerezyme, Myozyme/Lumizyme & Fabrazyme to its portfolio. Sanofi has become a major player in the CHC sector. It acquired many companies i.e. Ablynx & Bioverativ, Synthorx & Principia & Translate Bio and Kadmon. It has collaborated with companies like Regeneron among others. It develops and markets Dupixent, Kevzara & Libtayo in collaboration with Regeneron. Sanofi, along with Regeneron, is now solely responsible for Praluent marketing in & outside the U.S. Sanofi operates through 3 Global Business Units: Specialty Care (neurology & immunology, rare diseases, rare blood disorders & oncology), Vaccines & General Medicines (diabetes, cardiovascular & established products) and Consumer Healthcare, a standalone unit.
|
